Virax Biolabs Group Ltd Class A VRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
-
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
-
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
-
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
-
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
-
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
-
Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Trading Information
- Previous Close Price
- $3.89
- Day Range
- $3.73–3.95
- 52-Week Range
- $2.50–27.50
- Bid/Ask
- $3.72 / $3.77
- Shares Outstanding
- 796,988.00
- Market Cap
- $3.09M
- Volume/Avg
- 77,705 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 124.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.viraxbiolabs.com
Valuation
|
Metric
|
VRAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.30 |
Price/Sales | 124.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRAX
|
|---|---|
Quick Ratio | 9.44 |
Current Ratio | 9.97 |
Interest Coverage | −95.04 |
Quick Ratio
VRAX
Profitability
|
Metric
|
VRAX
|
|---|---|
Return on Assets (Normalized) | −77.98% |
Return on Equity (Normalized) | −85.87% |
Return on Invested Capital (Normalized) | −82.31% |
Return on Assets
VRAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#^B$<? | LOCK|r&%J | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|tlBQrz | LOCK|@T?rB | $71B | |||
| argenx SE ADR
ARGX
| LOCK|pKV@xtC | LOCK|&$% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k#C#kS$ | LOCK|@S% | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Ht>x$% | LOCK|#&fBV | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hmJ#pTrb | LOCK|@Zpk | $26B | |||
| Moderna Inc
MRNA
| LOCK|>yCbfY | LOCK|Z&X | $25B | |||
| Incyte Corp
INCY
| LOCK|RJ#h#S | LOCK|GB | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|TDHTPLR | LOCK|<Y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|nT>&$h? | LOCK|?<# | $16B |
United States